Summary of Product Characteristics and Patient Information Leaflet

Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable (see sections 4.4 and 5.1).

Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease

For Miglustat Summary of Product Characteristics, please click here.

For Miglustat Patient Information Leaflet, please click here.